<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, a columnar <z:mpath ids='MPATH_160'>metaplasia</z:mpath> of the lower esophagus epithelium related to <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo>, is the strongest known risk factor for the development of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EAC) </plain></SENT>
<SENT sid="1" pm="."><plain>Understanding the signal transduction events involved in esophageal epithelium <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> may provide insights into the origins of EAC and may suggest new therapies </plain></SENT>
<SENT sid="2" pm="."><plain>To elucidate the molecular pathways of <z:chebi fb="0" ids="3098">bile acid</z:chebi>-induced <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, the newly identified <z:mp ids='MP_0001845'>inflammation</z:mp>-associated signaling pathway involving I kappaB kinases beta (IKK beta), tuberous <z:mp ids='MP_0000612'>sclerosis</z:mp> complex 1 (TSC1), and mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) downstream effector S6 kinase (S6K1) was confirmed to be activated in immortalized Barrett's CPC-A and CPC-C cells and <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> SEG-1 and BE3 cells </plain></SENT>
<SENT sid="3" pm="."><plain>Phosphorylation of TSC1 and S6K1 was induced in response to <z:chebi fb="0" ids="3098">bile acid</z:chebi> stimulation </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment of these cells with the mTOR inhibitor <z:chebi fb="0" ids="9168">rapamycin</z:chebi> or the IKK beta inhibitor Bay 11-7082 suppressed <z:chebi fb="0" ids="3098">bile acid</z:chebi>-induced cell proliferation and anchorage-independent growth </plain></SENT>
<SENT sid="5" pm="."><plain>We next used an orthotopic rat model to evaluate the role of <z:chebi fb="0" ids="3098">bile acid</z:chebi> in the progression of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> to EAC </plain></SENT>
<SENT sid="6" pm="."><plain>Of interest, we found high expression of phosphorylated IKK beta (pIKK beta) and phosphorylated S6K1 (pS6K1) in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues and the Barrett's epithelium compared with <z:mpath ids='MPATH_458'>normal</z:mpath> epithelium </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, immunostaining of clinical EAC tissue specimens revealed that pIKK beta expression was strongly correlated with pS6K1 level </plain></SENT>
<SENT sid="8" pm="."><plain>Together, these results show that <z:chebi fb="0" ids="3098">bile acid</z:chebi> can deregulate TSC1/mTOR through IKK beta signaling, which may play a critical role in EAC progression </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, Bay 11-7082 and <z:chebi fb="0" ids="9168">rapamycin</z:chebi> may potentially be chemopreventive drugs against <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>-associated EAC </plain></SENT>
</text></document>